FDA Approves Orkambi for Children, Ages 6-11, with Cystic Fibrosis
Vertex Pharmaceuticals reported that the U.S. Food and Drug Administration (FDA) has granted approval for its cystic fibrosis (CF) drug Orkambi to be used to treat children, ages 6 to 11, who have two copies (one inherited from each parent) of the F508del mutation in the CFTR gene. Having two…